ketamine and Ulcer
ketamine has been researched along with Ulcer in 7 studies
Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.
ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.
Ulcer: A lesion on the surface of the skin or a mucous surface, produced by the sloughing of inflammatory necrotic tissue.
Research Excerpts
Excerpt | Relevance | Reference |
---|---|---|
"Long-term abuse of ketamine causes ketamine-induced cystitis." | 7.96 | Extracellular vesicles enhance oxidative stress through P38/NF-kB pathway in ketamine-induced ulcerative cystitis. ( Chen, SH; He, PJ; Jiang, ZW; Lu, Y; Mi, H; Xi, XJ; Zeng, JJ, 2020) |
"Immunoglobulin E, ketamine cystitis, interstitial cystitis." | 7.83 | The Role of Immunoglobulin E in the Pathogenesis of Ketamine Related Cystitis and Ulcerative Interstitial Cystitis: An Immunohistochemical Study. ( Hsu, YH; Jhang, JF; Jiang, YH; Kuo, HC, 2016) |
"This case series has described a new clinical entity of severe ulcerative cystitis as a result of chronic ketamine use." | 7.74 | Ketamine-associated ulcerative cystitis: a new clinical entity. ( Dickson, B; Shahani, R; Stewart, RJ; Streutker, C, 2007) |
"Ketamine-treated rats were found to display bladder hyperactivity." | 5.42 | Ketamine-induced ulcerative cystitis and bladder apoptosis involve oxidative stress mediated by mitochondria and the endoplasmic reticulum. ( Chuang, SM; Ho, WT; Jang, MY; Juan, YS; Lee, YL; Lin, RJ; Liu, KM; Long, CY; Lu, JH; Lu, MC; Wang, CC; Wu, WJ, 2015) |
"Long-term abuse of ketamine causes ketamine-induced cystitis." | 3.96 | Extracellular vesicles enhance oxidative stress through P38/NF-kB pathway in ketamine-induced ulcerative cystitis. ( Chen, SH; He, PJ; Jiang, ZW; Lu, Y; Mi, H; Xi, XJ; Zeng, JJ, 2020) |
"Immunoglobulin E, ketamine cystitis, interstitial cystitis." | 3.83 | The Role of Immunoglobulin E in the Pathogenesis of Ketamine Related Cystitis and Ulcerative Interstitial Cystitis: An Immunohistochemical Study. ( Hsu, YH; Jhang, JF; Jiang, YH; Kuo, HC, 2016) |
"This case series has described a new clinical entity of severe ulcerative cystitis as a result of chronic ketamine use." | 3.74 | Ketamine-associated ulcerative cystitis: a new clinical entity. ( Dickson, B; Shahani, R; Stewart, RJ; Streutker, C, 2007) |
"Ketamine-treated rats were found to display bladder hyperactivity." | 1.42 | Ketamine-induced ulcerative cystitis and bladder apoptosis involve oxidative stress mediated by mitochondria and the endoplasmic reticulum. ( Chuang, SM; Ho, WT; Jang, MY; Juan, YS; Lee, YL; Lin, RJ; Liu, KM; Long, CY; Lu, JH; Lu, MC; Wang, CC; Wu, WJ, 2015) |
Research
Studies (7)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (14.29) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (42.86) | 29.6817 |
2010's | 2 (28.57) | 24.3611 |
2020's | 1 (14.29) | 2.80 |
Authors
Authors | Studies |
---|---|
Xi, XJ | 1 |
Zeng, JJ | 1 |
Lu, Y | 1 |
Chen, SH | 1 |
Jiang, ZW | 1 |
He, PJ | 1 |
Mi, H | 1 |
Liu, KM | 1 |
Chuang, SM | 1 |
Long, CY | 1 |
Lee, YL | 1 |
Wang, CC | 1 |
Lu, MC | 1 |
Lin, RJ | 1 |
Lu, JH | 1 |
Jang, MY | 1 |
Wu, WJ | 1 |
Ho, WT | 1 |
Juan, YS | 1 |
Jhang, JF | 1 |
Hsu, YH | 1 |
Jiang, YH | 1 |
Kuo, HC | 1 |
Shahani, R | 2 |
Streutker, C | 1 |
Dickson, B | 1 |
Stewart, RJ | 2 |
Okon, T | 1 |
Gaertner, DJ | 1 |
Boschert, KR | 1 |
Schoeb, TR | 1 |
Clinical Trials (2)
Trial Overview
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Intravesical Injection of Dextrose to Improve Lower Urinary Tract Symptoms Caused by Chronic Cystitis[NCT04821882] | 29 participants (Actual) | Interventional | 2019-05-01 | Completed | |||
Oral Ketamine for Control of Chronic Pain in Children[NCT01369680] | Phase 1 | 12 participants (Actual) | Interventional | 2011-05-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Neurocognitive Effect
"Baseline neurocognitive testing will be done before study drug is given. Subjects will be reassessed for any changes in neurocognitive scores at end of dosing (week 2) and at three weeks off study drug (week 14). Significant changes were measured at week 14 compared to baseline. Week 2 was measured to inform future studies.~The neurocognitive scores are standardized scores with a mean of 100; low scores correlate with low neurocognitive function, while high scores correlate with high function. A significant change is defined as greater than or equal to 10% decrease in scores." (NCT01369680)
Timeframe: At 14 weeks
Intervention | participants (Number) |
---|---|
Ketamine 0.25 mg/kg/Dose | 0 |
Ketamine 0.5 mg/kg/Dose | 0 |
Ketamine 1 mg/kg/Dose | 0 |
Ketamine 1.5 mg/kg/Dose | 0 |
Norketamine Cmax (Measured in ng/mL).
Pharmacokinetic testing will be done during chronic ketamine administration on subjects consenting to additional testing one week into study drug administration. This is to further describe the activity of ketamine in the blood of children when administered chronically and to enable comparison of any clinical effect or toxicity with steady state levels of ketamine in children. (NCT01369680)
Timeframe: At week 1
Intervention | ng/mL (Mean) |
---|---|
Ketamine 0.25 mg/kg/Dose | 37.5 |
Ketamine 0.5 mg/kg/Dose | 135 |
Ketamine 1 mg/kg/Dose | 250 |
Number of Participants Tolerating Dose
According to CTCae any dose causing grade 2 or worse toxicity will be an untolerated dose. Tolerability is defined as ability to take the medication for 2 weeks without having a grade 2 or worse toxicity. (NCT01369680)
Timeframe: Up to 2 weeks
Intervention | participants (Number) |
---|---|
Ketamine 0.25 mg/kg/Dose | 3 |
Ketamine 0.5 mg/kg/Dose | 3 |
Ketamine 1 mg/kg/Dose | 3 |
Ketamine 1.5 mg/kg/Dose | 1 |
Pain Control
"Subjects will be assessed for clinically significant change in pain scores during and after study drug administration. Significant change in pain scores were determined at week 2, though week 14 scores were collected as well.~Participants with a 2 point (or greater) decrease in pain scores compared to baseline were considered to have responded. The NRS scale was used, the scale ranges from 0-10, with 10 being the most pain." (NCT01369680)
Timeframe: Week 2
Intervention | participants (Number) |
---|---|
Ketamine 0.25 mg/kg/Dose | 3 |
Ketamine 0.5 mg/kg/Dose | 0 |
Ketamine 1 mg/kg/Dose | 2 |
Ketamine 1.5 mg/kg/Dose | 0 |
Reviews
1 review available for ketamine and Ulcer
Article | Year |
---|---|
Ketamine: an introduction for the pain and palliative medicine physician.
Topics: Adult; Amines; Analgesics; Analgesics, Opioid; Central Nervous System; Cryoglobulinemia; Cyclohexane | 2007 |
Other Studies
6 other studies available for ketamine and Ulcer
Article | Year |
---|---|
Extracellular vesicles enhance oxidative stress through P38/NF-kB pathway in ketamine-induced ulcerative cystitis.
Topics: Apoptosis; Cell Line, Tumor; Cell Survival; Cystitis; Cytochalasin D; Extracellular Vesicles; Humans | 2020 |
Ketamine-induced ulcerative cystitis and bladder apoptosis involve oxidative stress mediated by mitochondria and the endoplasmic reticulum.
Topics: Animals; Antioxidants; Apoptosis; Apoptosis Regulatory Proteins; Biomarkers; Cystitis; Disease Model | 2015 |
The Role of Immunoglobulin E in the Pathogenesis of Ketamine Related Cystitis and Ulcerative Interstitial Cystitis: An Immunohistochemical Study.
Topics: Adult; Aged; Biomarkers; Cystitis, Interstitial; Female; Humans; Immunoglobulin E; Ketamine; Male; M | 2016 |
Ketamine-associated ulcerative cystitis: a new clinical entity.
Topics: Adult; Biopsy, Needle; Cystitis; Cystoscopy; Female; Follow-Up Studies; Humans; Ketamine; Male; Pent | 2007 |
Reply to letter-to-the-editor, Re: Shahani R, Streutker C, Dickson B, et al: Ketamine-associated ulcerative cystitis: a new clinical entity. Urology 69: 810-812, 2007.
Topics: Analgesics; Cystitis; Humans; Ketamine; Ulcer | 2008 |
Muscle necrosis in Syrian hamsters resulting from intramuscular injections of ketamine and xylazine.
Topics: Animals; Cricetinae; Drug Combinations; Female; Injections, Intramuscular; Ketamine; Mesocricetus; M | 1987 |